A Pivotal Study of OCU 310 in Patients with Chronic Dry Eye Disease

Trial Profile

A Pivotal Study of OCU 310 in Patients with Chronic Dry Eye Disease

Planning
Phase of Trial: Phase III

Latest Information Update: 22 Mar 2018

At a glance

  • Drugs Brimonidine/loteprednol-etabonate (Primary)
  • Indications Dry eyes
  • Focus Adverse reactions; Registrational; Therapeutic Use
  • Sponsors Ocugen
  • Most Recent Events

    • 22 Mar 2018 New trial record
    • 20 Mar 2018 According to an Ocugen media release, based on encouraging results of phase II proof-of-concept study (NCT03418727), the company remains on track to advance OCU310 into Phase 3 clinical study in the third quarter 2018.
    • 15 Mar 2018 According to the Ocugen media release, this trial is expected to start in 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top